Datasets:

mmitch25

/

sample_awards

like 0

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q382799

Affinity chromatography

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q425941

Protein A

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q7211373

Monoclonal antibodies

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q857815

Plug and play

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q909534

Mass transfer

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q382783

Chemical affinity

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q48969892

Affinity capture

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q170050

Chromatography

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q903485

Protein purification

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q65087614

Phase separation

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q2111958

Productivity

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q185357

Phase transition

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q905749

Ion chromatography

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q827792

Quality control

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q7248508

Programming productivity

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q271580

Electron affinity

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q906963

Resin casting

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q2079858

Side-by-side (vehicle)

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q422248

Monoclonal antibody

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q3816336

Agricultural productivity

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q628895

Workforce productivity

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q145205

Resin

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q3130283

List of purification methods in chemistry

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q5113746

Chromatography in blood processing

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q1339474

Maternal death

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q739897

Assay

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q54173

General Electric

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q2976049

Drug class

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q219285

Fusion

000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca

Abstract The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA) chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition, and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs, creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb. The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1) We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins, MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™. The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated, continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in their purification process is a capture step via Protein A chromatography, which requires expensive resin and equipment making it difficult and time consuming to execute at commercial scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in the bioprocessing industry with its lower cost and continuous process that offers faster mass transfer, milder elution conditions, and enhanced productivity.

Q17084289

Synthetic antibody

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q740460

Pressure vessel

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q6155882

Space missions

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q4043142

Module

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q132580

Recycling

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q25325287

Hollow fiber membrane

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q110516951

International Habitation Module

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q715223

Sound module

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q7070482

Nutrient cycle

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q774583

Solar panel

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q11449356

Space vehicle

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q3243428

Computer recycling

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q6453666

Modular programming

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q2918770

Shoulder-fired missile

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q6661273

Vessel

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q1145647

Paper recycling

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q1194111

Plastic recycling

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q810941

Battery recycling

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q1392857

Vehicle recycling

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q25271

International Space Station

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q39552

Pressure

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q1739331

Loadable kernel module

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q1201871

Platform supply vessel

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q81809

Atmospheric pressure

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q1261040

Pressure sensor

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q912009

Modularity

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q5227292

Data feed

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q161

Fiber

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q17105199

Environment Modules (software)

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q6889712

Modular decomposition

000e80047232b2c222bdd84df6731e882a4dd6bd

EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED.

Q988343

Blood vessel

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q228558

Polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q3394057

Polarization in astronomy

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q193760

Polarization (waves)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q1551060

Group polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q5367036

Social polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q6553479

Linear polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q1886497

Vacuum polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q1050425

Polarization density

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q2698605

Polarization (electrochemistry)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q962347

Spin polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q7602059

Starlight

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q28452348

C band (NATO)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q1641079

Hyperpolarization (physics)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q496997

Indication (medicine)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q7187858

Photon polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q11942175

Polarizer

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q4854235

Band diagram

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q806380

Electronic band structure

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q204260

Plane (tool)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q7554278

Reconfigurable antenna

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q2018880

S band

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q575724

Base

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q328998

Complex plane

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q17012331

Anatomical plane

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q4386425

Depolarizer

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q869891

Polarizability

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q21072584

Macrophage polarization

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q131214

Antenna (radio)

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q17152721

Shortwave bands

0010ba9fc8850d94dbbaf1f967bfa36e99369fdb

A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION

Q25110567

Frequency band

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q2715623

Social network

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q3277290

Force protection

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q11795082

Homeland defense

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q131454

Library of Congress

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q2273844

Social intelligence

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q5034471

Capability management

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q7075

Library

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q188860

Library (computing)

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q2297111

Social support

00122948ee5cffbed489ed69ff0bb46cef3bf8f7

In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense.

Q109406

Network